Quality standards supporting care for conditions. Prostate cancer Prostate cancer is the most common cancer in men, with 35,567 diagnosed in England in 2011. It is more common in men aged over 65 and as the population ages, more cases are expected to occur. NICE published a quality standard to help the NHS provide high…
uk: draft guidance on drug to treat advanced prostate cancer
UK: NICE published draft guidance in which enzalutamide is not recommended as a drug to treat advanced prostate cancer. It says enzalutamide. also called Xtandi, manufactured by Astellas Pharma) is not a cost effective, pre chemotherapy treatment with too many uncertainties associated with evidence provided by manufacturer. …more
UK: Treatment guides for treating kidney and prostate cancer
Final guidance on use of axitinib for treating kidney cancer and sipuleucel-T for prostate cancer. Guidance issued to the NHS today, recommends that the drug axitinib, known as Inlyta by Pfizer, should be available as a second line treatment for kidney cancer. A separate new guide did not recommended sipuleucel-T, known as Provenge, for treating…
Prostate cancer treatment too expensive!
Sipuleucel-T cost too high for prostate cancer patients Final draft guidance not recommending sipuleucel-T for use with: Prostate cancer in men whose disease has spread, Who have few symptoms and with disease not yet suitable for chemotherapy treatment. Evidence showed price to NHS too high for potential benefit it may provide to patients. Sipuleucel-T, known…